Free Trial
→ 'You'll own nothing and be happy' (it's not a theory anymore) (From Decentralized Masters) (Ad)tc pixel
NASDAQ:IRON

Disc Medicine Q1 2025 Earnings Report

Disc Medicine logo
$69.40 -0.69 (-0.98%)
As of 12:15 PM Eastern
This is a fair market value price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Disc Medicine EPS Results

Actual EPS
-$1.02
Consensus EPS
-$0.99
Beat/Miss
Missed by -$0.03
One Year Ago EPS
N/A

Disc Medicine Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Disc Medicine Announcement Details

Quarter
Q1 2025
Date
5/7/2025
Time
Before Market Opens
Conference Call Date
Wednesday, May 7, 2025
Conference Call Time
8:00AM ET

Upcoming Earnings

Disc Medicine's Q2 2026 earnings is estimated for Thursday, August 6, 2026, based on past reporting schedules, with a conference call scheduled on Friday, August 7, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

Disc Medicine's Q1 2025 Press ReleasePress Release
(8-K)
Disc Medicine's Q1 2025 Quarterly reportQuarterly report
(10-Q)

Disc Medicine Earnings Headlines

Disc Medicine Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
June 15 at 7:25 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/15/3312212/673/en/disc-medicine-investor-news-if-you-have-suffered-losses-in-disc-medicine-inc-nasdaq-iron-you-are-encouraged-to-contact-the-rosen-law-firm-about-your-rights.html
Disc Medicine, Inc. (IRON) Discusses Clinical Updates on Bitopertin, Selcodebart, and DISC-3405 and Strategic Outlook Transcript
June 15 at 4:04 PM  |  seekingalpha.comhttps://seekingalpha.com/article/4915032-disc-medicine-inc-iron-discusses-clinical-updates-on-bitopertin-selcodebart-and-discminus
This Could Be the Biggest Monetary Shift in 50 Years
Tucked inside U.S. Code Title 31, Section 5117 is a provision allowing the Treasury to reprice America's gold reserves from $42 per ounce to today's market value - a potential 107x shift. President Trump has signaled interest in returning the dollar to commodity-backed foundations. More than 60 million Americans can move a portion of their savings into physical gold, tax-free and penalty-free, before any policy change is announced. The 2026 Gold Guide explains exactly how to position your 401(k) or IRA outside the dollar-denominated system.tc pixel
June 16 at 1:00 AM  |  Americas Gold Company (Ad)
Disc Medicine, Inc. (IRON) Discusses Clinical Updates on Bitopertin, Selcodebart, and DISC-3405 and Strategic Outlook - Slideshow
June 15 at 10:03 AM  |  seekingalpha.comhttps://seekingalpha.com/article/4915034-disc-medicine-inc-iron-discusses-clinical-updates-on-bitopertin-selcodebart-and-discminus
Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON
June 14 at 9:46 AM  |  prnewswire.comhttps://www.prnewswire.com/news-releases/rosen-law-firm-encourages-disc-medicine-inc-investors-to-inquire-about-securities-class-action-investigation--iron-302799479.html
ROSEN, LEADING INVESTOR COUNSEL, Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON
June 13 at 11:31 AM  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/rosen-leading-investor-counsel-encourages-disc-medicine-inc.-investors-to-inquire-about-securities-class-action-investigation-iron-1036081778
See More Disc Medicine Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Disc Medicine? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Disc Medicine and other key companies, straight to your email.

About Disc Medicine

Disc Medicine (NASDAQ:IRON) (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company's pipeline is anchored by lead programs targeting neuromuscular and hematological disorders. Disc Medicine's technology enables the discovery of novel modulators of pre-mRNA splicing and RNA–protein interactions, with therapeutic candidates advancing through preclinical development. These programs illustrate the company's commitment to translating fundamental insights in RNA biology into first-in-class or best-in-class therapies. Disc Medicine also explores oncology and rare disease indications through selective targeting of disease-driving RNA-binding proteins.

Based in Cambridge, Massachusetts, Disc Medicine was founded in 2019 by a team of drug discovery scientists and RNA biologists. Since its inception, the company has established collaborations with academic institutions and research organizations to accelerate its discovery efforts. Disc Medicine's executive leadership and scientific advisory board bring extensive expertise in medicinal chemistry, structural biology and clinical development, positioning the company to advance its novel therapeutic candidates toward human trials.

View Disc Medicine Profile
Earnings Tools